A five-year secondary analysis of the phase 2 PHERGain trial supports a PET-guided adaptive strategy that reduces chemotherapy in HER2-positive early breast cancer, while exploratory circulating tumor DNA findings may shape future treatment decisions.
You must log in or register to comment.
Five years of “strong outcomes” and we’re still handing out the same chemo to everyone and calling it progress. Wait for the phase 3 before anyone sells this as the new standard.
